EichorEICHOR
Condition: Pheochromocytomas Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Pheochromocytomas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03206060Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor
Phase 2 · 84 location(s) · Merck Sharp & Dohme LLC · NCT04924075Natural History Study of Children and Adults With Medullary Thyroid Cancer
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01660984Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Phase 2 · 1 location(s) · José Claudio Casali da Rocha · NCT07167329Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Project: Every Child for Younger Patients With Cancer
Phase N/A · 278 location(s) · Children's Oncology Group · NCT02402244An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT0707214318F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT05069220Using the EHR to Advance Genomic Medicine Across a Diverse Health System
NA · 1 location(s) · University of Pennsylvania · NCT06377033HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 5 location(s) · Cancer Research UK · NCT05944237[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors,
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06479811Multicenter Pheochromocytoma and Paraganglioma Evaluation
NA · 1 location(s) · Felix Beuschlein · NCT03344016Diagnosis of Pheochromocytoma
Phase 1 · 1 location(s) · Eunice Kennedy Shriver National Institute of Child Health an · NCT00004847Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging
Phase N/A · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT07195500Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
NA · 1 location(s) · Peking Union Medical College Hospital · NCT07288931Adrenal Tumors - Pathogenesis and Therapy
Phase N/A · 1 location(s) · University of Wuerzburg · NCT00669266Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Phase N/A · 3 location(s) · Universidad Nacional Autonoma de Mexico · NCT06523582An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
Phase 2 · 1 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT07680205Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT00001238Hereditary Pheochromocytoma Assessment of Tumour Immunologies
Phase N/A · 1 location(s) · Radboud University Medical Center · NCT06444607In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
EARLY_Phase 1 · 1 location(s) · Heather Wachtel · NCT05636540Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Phase N/A · 1 location(s) · The University of Texas Health Science Center at San Antonio · NCT03160274A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06041516Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06427798Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT0604526018F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06503146Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Ma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT00107289
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.